Phenotypes associated with this allele

• Allele Symbol: Brca2^tm1Brn
• Allele Name: targeted mutation 1, Anton Berns
• Allele ID: MGI:2156556
• Summary: 19 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Brca2^tm1Brn/Brca2^tm1Brn	involves: 129P2/OlaHsd * FVB/N	MGI:3831426
cn2	Brca2^tm1Brn/Brca2^tm1Brn Ptch1^tm1Mps/Ptch1^+ Trp53^tm1Tyj/Trp53^tm1Tyj Tg(Nes-cre)1Kln/0	involves: 129 * C57BL/6 * SJL	MGI:3831343
cn3	Brca2^tm1Brn/Brca2^tm1Brn Ptch1^tm1Mps/Ptch1^+ Trp53^tm1Tyj/Trp53^+ Tg(Nes-cre)1Kln/0	involves: 129 * C57BL/6 * SJL	MGI:3831342
cn4	Brca2^tm1Brn/Brca2^tm1Brn Trp53bp1^tm1Jc/Trp53bp1^tm1Jc Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:5495980
cn5	Brca2^tm1Brn/Brca2^tm1Brn Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd	MGI:5495979
cn6	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Tyj/Trp53^tm1Tyj Tg(Nes-cre)1Kln/0	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL	MGI:3831341
cn7	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Tyj/Trp53^+ Tg(Nes-cre)1Kln/0	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL	MGI:3831340
cn8	Brca2^tm1Brn/Brca2^tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53^tm1Brn/Trp53^tm2Tyj	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N	MGI:5617497
cn9	Brca2^tm1Brn/Brca2^tm1Cam Kras^tm4Tyj/Kras^+ Trp53^tm3Tyj/Trp53^+ Tg(Pdx1-cre)6Tuv/0	involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N	MGI:4940096
cn10	Brca2^tm1Cam/Brca2^tm1Brn Kras^tm4Tyj/Kras^+ Tg(Pdx1-cre)6Tuv/0	involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N	MGI:4940102
cn11	Brca2^tm1Cam/Brca2^tm1Brn Tg(Pdx1-cre)6Tuv/0 Trp53^tm3Tyj/Trp53^+	involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N	MGI:4940104
cn12	Brca2^tm1Cam/Brca2^tm1Brn Tg(Pdx1-cre)6Tuv/0	involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6 * FVB/N	MGI:4940106
cn13	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53^+ Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4819194
cn14	Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4819192
cn15	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4819193
cn16	Brca2^tm1Brn/Brca2^tm1Brn Tg(Nes-cre)1Kln/0	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:3831339
cn17	Brca2^tm1Brn/Brca2^+ Trp53^tm1Brn/Trp53^tm1Brn Tg(KRT14-cre)8Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3831431
cn18	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(KRT14-cre)8Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3831430
cn19	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53^+ Tg(KRT14-cre)8Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3831432

Genotype
MGI:3831426

hm1

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:73028 )

• mice exhibit normal development and lifespan

Genotype
MGI:3831343

cn2

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Ptch1^tm1Mps/Ptch1⁺; Trp53^tm1Tyj/Trp53^tm1Tyj; Tg(Nes-cre)1Kln/0
• Genetic Background: involves: 129 * C57BL/6 * SJL

neoplasm

increased medulloblastoma incidence ( J:144617 )

• 100% of mice develop medulloblastoma beginning at 5 weeks

nervous system

increased medulloblastoma incidence ( J:144617 )

• 100% of mice develop medulloblastoma beginning at 5 weeks

Genotype
MGI:3831342

cn3

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Ptch1^tm1Mps/Ptch1⁺; Trp53^tm1Tyj/Trp53⁺; Tg(Nes-cre)1Kln/0
• Genetic Background: involves: 129 * C57BL/6 * SJL

neoplasm

increased medulloblastoma incidence ( J:144617 )

• 100% of mice develop medulloblastoma beginning at 10 weeks

nervous system

increased medulloblastoma incidence ( J:144617 )

• 100% of mice develop medulloblastoma beginning at 10 weeks

Genotype
MGI:5495980

cn4

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53bp1^tm1Jc/Trp53bp1^tm1Jc; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

cellular

chromosome breakage ( J:197442 )

• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with cells from Brca2^tm1Brn/Brca2^tm1Brn Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn mice

Genotype
MGI:5495979

cn5

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd

cellular

chromosome breakage ( J:197442 )

• cells treated with PARP-inhibition exhibit increased chromosomal damage compared with untreated cells

Genotype
MGI:3831341

cn6

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Tyj/Trp53^tm1Tyj; Tg(Nes-cre)1Kln/0
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL

neoplasm

increased medulloblastoma incidence ( J:144617 )

• 87% of mice develop medulloblastoma beginning at 13 weeks

nervous system

increased medulloblastoma incidence ( J:144617 )

• 87% of mice develop medulloblastoma beginning at 13 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:144617

Genotype
MGI:3831340

cn7

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Tyj/Trp53⁺; Tg(Nes-cre)1Kln/0
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL

neoplasm

abnormal tumor morphology ( J:144617 )

• tumors exhibit a loss of heterozygosity at the Trp53 gene

increased medulloblastoma incidence ( J:144617 )

• 72% of mice develop medulloblastoma beginning at 21 weeks

nervous system

increased medulloblastoma incidence ( J:144617 )

• 72% of mice develop medulloblastoma beginning at 21 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:144617

Genotype
MGI:5617497

cn8

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Tg(Krt18-EGFP,-TAg121)36Ysng/0; Trp53^tm1Brn/Trp53^tm2Tyj
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N

neoplasm

increased ovary tumor incidence ( J:189304 )

♀ • 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands

increased ovary tumor incidence ( J:189304 )

♀ • 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system

increased ovary tumor incidence ( J:189304 )

♀ • 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:189304

Genotype
MGI:4940096

cn9

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Cam; Kras^tm4Tyj/Kras⁺; Trp53^tm3Tyj/Trp53⁺; Tg(Pdx1-cre)6Tuv/0
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N

neoplasm

increased pancreatic acinar cell carcinoma incidence ( J:166678 )

• about 18% of assessable tumor cases develop an acinar-cell carcinoma component of pancreatic tumors

increased pancreatic ductal adenocarcinoma incidence ( J:166678 )

• high penetrance (29 of 30 mutants) of pancreatic ductal adenocarcinomas

mortality/aging

premature death ( J:166678 )

• average survival time is 84 days, with a range of 48-110 days

endocrine/exocrine glands

increased pancreatic acinar cell carcinoma incidence ( J:166678 )

• about 18% of assessable tumor cases develop an acinar-cell carcinoma component of pancreatic tumors

increased pancreatic ductal adenocarcinoma incidence ( J:166678 )

• high penetrance (29 of 30 mutants) of pancreatic ductal adenocarcinomas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic carcinoma		DOID:4905	OMIM:260350	J:166678

Genotype
MGI:4940102

cn10

• Allelic Composition: Brca2^tm1Cam/Brca2^tm1Brn; Kras^tm4Tyj/Kras⁺; Tg(Pdx1-cre)6Tuv/0
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N

digestive/alimentary system

exocrine pancreatic insufficiency ( J:166678 )

• pancreatic insufficiency; spectrum of anomalies are seen from isolated paucity of the islets of Langerhans to complete fibro-inflammatory or cystic degeneration of both the endocrine and exocrine pancreas

endocrine/exocrine glands

increased pancreas apoptosis ( J:166678 )

• pancreata from 6 day old mutants exhibits an increase in apoptotic cells compared to controls

exocrine pancreatic insufficiency ( J:166678 )

• pancreatic insufficiency; spectrum of anomalies are seen from isolated paucity of the islets of Langerhans to complete fibro-inflammatory or cystic degeneration of both the endocrine and exocrine pancreas

increased pancreatic ductal adenocarcinoma incidence ( J:166678 )

• mutants not succumbing to pancreatic insufficiency later develop pancreatic ductal adenocarcinomas with a moderate latency and incomplete penetrance (6 of 32 mutants)

mortality/aging

premature death ( J:166678 )

• mutants exhibit shortened pancreatic ductal adenocarcinoma-free survival

neoplasm

increased pancreatic ductal adenocarcinoma incidence ( J:166678 )

• mutants not succumbing to pancreatic insufficiency later develop pancreatic ductal adenocarcinomas with a moderate latency and incomplete penetrance (6 of 32 mutants)

cellular

increased pancreas apoptosis ( J:166678 )

• pancreata from 6 day old mutants exhibits an increase in apoptotic cells compared to controls

Genotype
MGI:4940104

cn11

• Allelic Composition: Brca2^tm1Cam/Brca2^tm1Brn; Tg(Pdx1-cre)6Tuv/0; Trp53^tm3Tyj/Trp53⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N

digestive/alimentary system

exocrine pancreatic insufficiency ( J:166678 )

• pancreatic insufficiency is occasionally observed in mutants

endocrine/exocrine glands

exocrine pancreatic insufficiency ( J:166678 )

• pancreatic insufficiency is occasionally observed in mutants

mortality/aging

premature death ( J:166678 )

• premature death before 600 days of age due to lymphoid malignancies and sarcomas

neoplasm

increased malignant tumor incidence ( J:166678 )

• mutants develop lymphoid malignancies

increased sarcoma incidence ( J:166678 )

Genotype
MGI:4940106

cn12

• Allelic Composition: Brca2^tm1Cam/Brca2^tm1Brn; Tg(Pdx1-cre)6Tuv/0
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6 * FVB/N

digestive/alimentary system

exocrine pancreatic insufficiency ( J:166678 )

• small fraction of mutants develop pancreatic insufficiency

endocrine/exocrine glands

exocrine pancreatic insufficiency ( J:166678 )

• small fraction of mutants develop pancreatic insufficiency

mortality/aging

premature death ( J:166678 )

• premature death in the small fraction of mutants with pancreatic insufficiency

Genotype
MGI:4819194

cn13

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Brn/Trp53⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

High-grade prostate intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0 Trp53^tm1Brn/Trp53^tm1Brn and prostate hyperplasia and intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53⁺ Tg(Pbsn-cre)4Prb/0 mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen at 10 - 14 months of age

♂ • by 15 - 20 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • levels of cell proliferation are 9 fold higher in PIN lesions

reproductive system

abnormal prostate gland morphology ( J:161511 )

♂ • focal hyperplasia is seen beginning at 10 -14 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen at 10 - 14 months of age

♂ • by 15 - 20 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • levels of cell proliferation are 9 fold higher in PIN lesions

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 4 fold increase in apoptotic cells in PIN foci

endocrine/exocrine glands

abnormal prostate gland morphology ( J:161511 )

♂ • focal hyperplasia is seen beginning at 10 -14 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen at 10 - 14 months of age

♂ • by 15 - 20 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • levels of cell proliferation are 9 fold higher in PIN lesions

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 4 fold increase in apoptotic cells in PIN foci

Genotype
MGI:4819192

cn14

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

Prostate hyperplasia and low-grade prostate intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0 mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • hyperplasia and low grade PIN are seen all 4 lobes

♂ • focal low grade PIN are seen in the lumen at 15 - 20 months of age

♂ • low grade PIN lesions form characteristic tufting and cribiform patterns

reproductive system

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia containing atypical cells is seen beginning at 10 -14 months of age

♂ • hyperplasia and low grade PIN are seen all 4 lobes

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen in the lumen at 15 - 20 months of age

♂ • low grade PIN lesions form characteristic tufting and cribiform patterns

♂ • hyperplasia and low grade PIN are seen all 4 lobes

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 3 fold increase in apoptotic cells in areas of hyperplasia and low grade PIN

endocrine/exocrine glands

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia containing atypical cells is seen beginning at 10 -14 months of age

♂ • hyperplasia and low grade PIN are seen all 4 lobes

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen in the lumen at 15 - 20 months of age

♂ • low grade PIN lesions form characteristic tufting and cribiform patterns

♂ • hyperplasia and low grade PIN are seen all 4 lobes

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 3 fold increase in apoptotic cells in areas of hyperplasia and low grade PIN

Genotype
MGI:4819193

cn15

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

High-grade prostate intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0 Trp53^tm1Brn/Trp53^tm1Brn and prostate hyperplasia and intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53⁺ Tg(Pbsn-cre)4Prb/0 mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • by 10 - 14 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • frequently multiple ducts of each lobe have high grade PIN, which are present in proximal and distal regions of the prostate and consist of many atypical cells filling the lumen

♂ • high grade PIN lesions are predominantly seen in the anterior and dorsal prostate

♂ • levels of cell proliferation are 30 fold higher in PIN lesions

♂ • high grade PIN lesions frequently contain large groups of basal cells some of which are rounder in shape and positioned near the lumen

♂ • high grade lesions continue to proliferate post castration

reproductive system

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia is seen beginning as early as 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • by 10 - 14 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • frequently multiple ducts of each lobe have high grade PIN, which are present in proximal and distal regions of the prostate and consist of many atypical cells filling the lumen

♂ • high grade PIN lesions are predominantly seen in the anterior and dorsal prostate

♂ • levels of cell proliferation are 30 fold higher in PIN lesions

♂ • high grade PIN lesions frequently contain large groups of basal cells some of which are rounder in shape and positioned near the lumen

♂ • high grade lesions continue to proliferate post castration

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 20 fold increase in apoptotic cells in areas of high grade PIN

endocrine/exocrine glands

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia is seen beginning as early as 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • by 10 - 14 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • frequently multiple ducts of each lobe have high grade PIN, which are present in proximal and distal regions of the prostate and consist of many atypical cells filling the lumen

♂ • high grade PIN lesions are predominantly seen in the anterior and dorsal prostate

♂ • levels of cell proliferation are 30 fold higher in PIN lesions

♂ • high grade PIN lesions frequently contain large groups of basal cells some of which are rounder in shape and positioned near the lumen

♂ • high grade lesions continue to proliferate post castration

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 20 fold increase in apoptotic cells in areas of high grade PIN

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:161511

Genotype
MGI:3831339

cn16

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Tg(Nes-cre)1Kln/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

nervous system

nervous system phenotype ( J:144617 )

N • compared to germ line deletions of this gene, mice exhibit no increase in apoptosis during neural development

Genotype
MGI:3831431

cn17

• Allelic Composition: Brca2^tm1Brn/Brca2⁺; Trp53^tm1Brn/Trp53^tm1Brn; Tg(KRT14-cre)8Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased tumor incidence ( J:73028 )

• mice develop tumors with a short median latency period of 298 days

• tumors exhibit expansive growth pattern, a high nuclear grade, and a high mitotic index

increased mammary gland tumor incidence ( J:73028 )

• in 55% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

increased skin tumor incidence ( J:73028 )

• mice develop skin carcinomas

integument

increased mammary gland tumor incidence ( J:73028 )

• in 55% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

increased skin tumor incidence ( J:73028 )

• mice develop skin carcinomas

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:73028 )

• in 55% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

Genotype
MGI:3831430

cn18

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(KRT14-cre)8Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased tumor incidence ( J:73028 )

• mice develop tumors with a short median latency period of 181 days

• tumors exhibit expansive growth pattern, a high nuclear grade, and a high mitotic index

increased mammary gland tumor incidence ( J:73028 )

• in 72% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

increased skin tumor incidence ( J:73028 )

• mice develop skin carcinomas

integument

increased mammary gland tumor incidence ( J:73028 )

• in 72% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

increased skin tumor incidence ( J:73028 )

• mice develop skin carcinomas

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:73028 )

• in 72% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:73028

Genotype
MGI:3831432

cn19

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Brn/Trp53⁺; Tg(KRT14-cre)8Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased tumor incidence ( J:73028 )

• mice develop tumors with a short median latency period of 360 days

• tumors exhibit expansive growth pattern, a high nuclear grade, and a high mitotic index

increased mammary gland tumor incidence ( J:73028 )

• in 31% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

increased skin tumor incidence ( J:73028 )

• mice develop skin carcinomas

integument

increased mammary gland tumor incidence ( J:73028 )

• in 31% of mice

increased mammary adenocarcinoma incidence ( J:73028 )

increased skin tumor incidence ( J:73028 )

• mice develop skin carcinomas

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:73028 )

• in 31% of mice

increased mammary adenocarcinoma incidence ( J:73028 )